These studies demonstrate a potential role for HIF2α activation in decreasing the capacity for FAO in the liver, which could worsen steatosis in the context of NAFLD, when dietary fat intake is typically high. Here, EPAS1 is linked to metabolic dysfunction-associated steatotic liver disease.